Inhalation Sciences AB (ISAB) has announced that former ExScale Bio CEO Manoush Masarrat, who has been a member of the ISAB board of directors since January 2019, will succeed Lena Heffler as ISAB CEO. In addition to his most recent position as CEO of ExScale Bio, Masarrat has also served in sales and marketing roles at a number of companies, including Medical Vision, … [Read more...] about Inhalation Sciences names Manoush Masarrat as CEO
News
TerrAscend to distribute Syqe inhaler in Canada
Canadian-based cannabis company TerrAscend has acquired exclusive distribution rights to Syqe Medical's Syqe medical cannabis inhaler in Canada, the companies announced. The Syqe inhaler, which uses cartridges loaded with medical cannabis plant material, has been available to patients for the treatment of pain in Israel since June 2019; previously, the inhaler was … [Read more...] about TerrAscend to distribute Syqe inhaler in Canada
Judge increases award to Vectura in Ellipta case
Ruling on post-trial motions in a case in which a jury found in May 2019 that GSK had willfully infringed on a Vectura patent covering Ellipta, the presiding judge has upheld the jury's award of $89.7 million in damages to Vectura and has added an additional $10.5 million in damages based on GSK's continued infringement. The original award was based on 3% … [Read more...] about Judge increases award to Vectura in Ellipta case
Optinose announces $150 million debt financing from Pharmakon Advisors
Intranasal drug developer Optinose announced that it has issued $80 million in senior secured notes as part of a $150 million debt financing agreement with Pharmakon Advisors. The company plans to issue another $30 million in notes by mid-February 2020, "subject to the achievement of minimum Xhance revenues and certain other conditions." Optinose's Xhance fluticasone … [Read more...] about Optinose announces $150 million debt financing from Pharmakon Advisors
Satsuma looks to raise $82.5 million in IPO for continued development of intranasal DHE
Satsuma Pharmaceuticals has announced an underwritten initial public offering of 5,500,000 shares of its common stock at $15.00 per share, with expected gross proceeds of $82.5 million. The underwriters of the offering also get a 30-day option to purchase additional shares of common stock (up to a total of 825,000 shares) at the same price. The company's common stock … [Read more...] about Satsuma looks to raise $82.5 million in IPO for continued development of intranasal DHE
Dance Biopharm announces deal with DarioHealth
Inhaled insulin developer Dance Biopharm announced that it has signed an agreement with DarioHealth to integrate its smart soft mist inhaler into DarioHealth's digital platform. The integration, which will allow patients using the SMI to get usage data in real time through a mobile app, is expected to be completed in time for upcoming clinical trials and would be … [Read more...] about Dance Biopharm announces deal with DarioHealth
US Patent Trial and Appeal Board grants inter partes review of Narcan patent
The US Patent Trial and Appeal Board (PTAB) has instituted an inter partes review of US Patent No. 9,211,253, "Nasal drug products and methods of their use." That patent, which covers Opiant Pharmaceutical's Narcan intranasal naloxone for the reversal of opioid overdose through 2035, was granted to Lightlake Therapeutics (now Opiant) in December 2015. Adapt … [Read more...] about US Patent Trial and Appeal Board grants inter partes review of Narcan patent
Santhera publishes data from Phase 1 study of its inhaled hNE inhibitor
Santhera Pharmaceuticals has announced the publication of data from two Phase 1 studies of its POL6014 inhaled human neutrophil elastase (hNE) inhibitor in the Journal of Cystic Fibrosis. According to the company, inhalation of nebulized POL6014 resulted in a rapid reduction of hNE in the sputum of cystic fibrosis patients, with high lung concentrations of POL6014 … [Read more...] about Santhera publishes data from Phase 1 study of its inhaled hNE inhibitor
Tiziana announces Phase 1 results for intranasal Foralumab
Tiziana Life Sciences has announced that a Phase 1 clinical trial of its intranasal Foralumab human anti-CD3 monoclonal antibody was well tolerated at doses of 10, 50 and 250 µg per day and demonstrated "significant positive immune effects." The company is developing intranasal Foralumab, which it licensed from Novimmune in 2014, for the treatment of neurodegenerative … [Read more...] about Tiziana announces Phase 1 results for intranasal Foralumab
Milestone Pharmaceuticals announces appointment of Amit Hasija as CFO and Executive VP of Corporate Development
Milestone Pharmaceuticals has announced the appointment of former Sanofi executive Amit Hasija as Chief Financial Officer and Executive VP of Corporate Development. Milestone's etripamil, an intranasal calcium channel antagonist, is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia (PSVT). Hasija was most recently Chief Business … [Read more...] about Milestone Pharmaceuticals announces appointment of Amit Hasija as CFO and Executive VP of Corporate Development